167 related articles for article (PubMed ID: 24831963)
1. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
2. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Han K; Xu X; Chen G; Zeng Y; Zhu J; Du X; Zhang Z; Cao B; Liu Z; Mao X
J Hematol Oncol; 2014 Jan; 7():9. PubMed ID: 24428908
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Carver BS; Chapinski C; Wongvipat J; Hieronymus H; Chen Y; Chandarlapaty S; Arora VK; Le C; Koutcher J; Scher H; Scardino PT; Rosen N; Sawyers CL
Cancer Cell; 2011 May; 19(5):575-86. PubMed ID: 21575859
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
[TBL] [Abstract][Full Text] [Related]
5. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
6. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
7. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
8. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
11. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
12. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
13. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
14. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
[TBL] [Abstract][Full Text] [Related]
15. Phenoxodiol inhibits growth of metastatic prostate cancer cells.
Aguero MF; Venero M; Brown DM; Smulson ME; Espinoza LA
Prostate; 2010 Aug; 70(11):1211-21. PubMed ID: 20564423
[TBL] [Abstract][Full Text] [Related]
16. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
17. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
20. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Lee TJ; Sartor O; Luftig RB; Koochekpour S
Mol Cancer; 2004 Nov; 3():31. PubMed ID: 15548330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]